88 related articles for article (PubMed ID: 2126903)
1. The cost-effectiveness of prevention of post-operative thromboembolism.
Bergqvist D; Mätzsch T; Jendteg S; Lindgren B; Persson U
Acta Chir Scand Suppl; 1990; 556():36-41. PubMed ID: 2126903
[TBL] [Abstract][Full Text] [Related]
2. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
Haentjens P; De Groote K; Annemans L
Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
[TBL] [Abstract][Full Text] [Related]
3. Thromboembolic prophylaxis in moderate-risk patients undergoing elective abdominal surgery: decision and cost-effectiveness analyses.
Mamdani MM; Weingarten CM; Stevenson JG
Pharmacotherapy; 1996; 16(6):1111-27. PubMed ID: 8947985
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery.
Menzin J; Colditz GA; Regan MM; Richner RE; Oster G
Arch Intern Med; 1995 Apr; 155(7):757-64. PubMed ID: 7695464
[TBL] [Abstract][Full Text] [Related]
5. [Cost-effectiveness of the prevention of postoperative thromboembolism].
Bergqvist D; Mätzsch T
Orthopade; 1993 Apr; 22(2):140-3. PubMed ID: 8388560
[TBL] [Abstract][Full Text] [Related]
6. Out of hospital antithrombotic prophylaxis after total hip replacement: low-molecular-weight heparin, warfarin, aspirin or nothing? A cost-effectiveness analysis.
Sarasin FP; Bounameaux H
Thromb Haemost; 2002 Apr; 87(4):586-92. PubMed ID: 12008939
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of venous thromboembolism prophylaxis in surgery.
Bergqvist D
Eur J Surg Suppl; 1994; (571):49-53. PubMed ID: 7519090
[No Abstract] [Full Text] [Related]
8. The incremental cost effectiveness of in-patient versus out-patient rehabilitation after total hip arthroplasty - results of a pilot investigation.
Krummenauer F; Günther KP; Witzlebf WC
Eur J Med Res; 2008 Jun; 13(6):267-74. PubMed ID: 18558552
[TBL] [Abstract][Full Text] [Related]
9. Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective.
Hull RD; Raskob GE; Pineo GF; Feldstein W; Rosenbloom D; Gafni A; Green D; Feinglass J; Trowbridge AA; Elliott CG
Arch Intern Med; 1997 Feb; 157(3):298-303. PubMed ID: 9040296
[TBL] [Abstract][Full Text] [Related]
10. Cost implications of low molecular weight heparins as prophylaxis following total hip and knee replacement.
Bell GK; Goldhaber SZ
Vasc Med; 2001; 6(1):23-9. PubMed ID: 11358156
[TBL] [Abstract][Full Text] [Related]
11. Cost-benefit analysis of prophylaxis against deep vein thrombosis in surgery.
Hauch O; Khattar SC; Jørgensen LN
Semin Thromb Hemost; 1991; 17 Suppl 3():280-3. PubMed ID: 1661436
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of prolonged administration of a low molecular weight heparin for the prevention of deep venous thrombosis following total hip replacement.
Bergqvist D; Jönsson B
Value Health; 1999; 2(4):288-94. PubMed ID: 16674319
[TBL] [Abstract][Full Text] [Related]
13. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
Kakkar VV; Howes J; Sharma V; Kadziola Z
Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310
[TBL] [Abstract][Full Text] [Related]
14. The Otto Aufranc Award paper. New advances in the prevention, diagnosis, and cost effectiveness of venous thromboembolic disease in patients with total hip replacement.
Paiement GD; Bell D; Wessinger SJ; Harris WH
Hip; 1987; ():94-119. PubMed ID: 3102409
[No Abstract] [Full Text] [Related]
15. Economic evaluation of enoxaparin as prophylaxis against venous thromboembolism in seriously ill medical patients: a US perspective.
de Lissovoy G; Subedi P
Am J Manag Care; 2002 Dec; 8(12):1082-8. PubMed ID: 12500884
[TBL] [Abstract][Full Text] [Related]
16. Long-term cost-effectiveness of low molecular weight heparin versus unfractionated heparin for the prophylaxis of venous thromboembolism in elective hip replacement.
Marchetti M; Liberato NL; Ruperto N; Barosi G
Haematologica; 1999 Aug; 84(8):730-7. PubMed ID: 10458700
[TBL] [Abstract][Full Text] [Related]
17. Management of venous thromboembolic disease. The impact of low-molecular-weight heparin.
Tapson VF; Hull RD
Clin Chest Med; 1995 Jun; 16(2):281-94. PubMed ID: 7656540
[TBL] [Abstract][Full Text] [Related]
18. [Incremental cost effectiveness of multifocal cataract surgery].
Pagel N; Dick HB; Krummenauer F
Klin Monbl Augenheilkd; 2007 Feb; 224(2):101-9. PubMed ID: 17309005
[TBL] [Abstract][Full Text] [Related]
19. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
Míka P; Behounek J; Skoták M; Nevsímal L
Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
[TBL] [Abstract][Full Text] [Related]
20. Comparing the costs, risks, and benefits of competing strategies for the primary prevention of venous thromboembolism.
Avorn J; Winkelmayer WC
Circulation; 2004 Dec; 110(24 Suppl 1):IV25-32. PubMed ID: 15598645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
